Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Construction in Progress (2018 - 2023)

China SXT Pharmaceuticals has reported Construction in Progress over the past 6 years, most recently at $349390.0 for Q1 2023.

  • For Q1 2023, Construction in Progress fell 3.77% year-over-year to $349390.0; the TTM value through Mar 2023 reached $349390.0, down 3.77%, while the annual FY2023 figure was $349390.0, 3.77% down from the prior year.
  • Construction in Progress for Q1 2023 was $349390.0 at China SXT Pharmaceuticals, up from $343153.0 in the prior quarter.
  • Over five years, Construction in Progress peaked at $649235.0 in Q1 2019 and troughed at -$114286.0 in Q3 2020.
  • A 5-year average of $312569.4 and a median of $349390.0 in 2023 define the central range for Construction in Progress.
  • Biggest five-year swings in Construction in Progress: crashed 163.49% in 2020 and later surged 413.75% in 2021.
  • Year by year, Construction in Progress stood at $180000.0 in 2019, then plummeted by 163.49% to -$114286.0 in 2020, then surged by 413.75% to $358569.0 in 2021, then dropped by 4.3% to $343153.0 in 2022, then rose by 1.82% to $349390.0 in 2023.
  • Business Quant data shows Construction in Progress for SXTC at $349390.0 in Q1 2023, $343153.0 in Q3 2022, and $363078.0 in Q1 2022.